Change in Concomitant Immunosuppressive Therapies for Generalized Myasthenia Gravis in Patients Receiving Complement C5 Inhibitor Therapies: A Retrospective Analysis of Registry Data (P7-11.028)
Describe changes in the use of concomitant immunosuppressive therapies (IST) after initiation of eculizumab and/or ravulizumab treatment.
Authors
- Andrew M. Gordon (ORCID: https://orcid.org/0000-0003-1041-0479)
- Pushpa Narayanaswami (ORCID: https://orcid.org/0000-0002-9412-7349)
- Chuang Liu (ORCID: https://orcid.org/0000-0002-5573-738X)
- Richard J. Nowak (ORCID: https://orcid.org/0000-0001-8438-482X)
- Lida Zeinali
- Christopher A. Scheiner
- Michael Pulley (ORCID: https://orcid.org/0000-0003-1879-725X)
- Ali A. Habib (ORCID: https://orcid.org/0000-0003-3432-9747)
Institutions
- University of California, Irvine (US)
- Hadassah Medical Center (IL)
- University of Tennessee Medical Center (US)
- Yale University (US)
- University of Florida (US)
- Endocrinology Northwest (US)
- AstraZeneca (Brazil) (BR)
- Alexion Pharma (Switzerland) (CH)
- University of Tennessee at Knoxville (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208777
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00